LINCOLN, Mass., Sept. 12, 2016 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug invention, today announced an agreement with Jounce Therapeutics for clinical pharmacology and quantitative systems pharmacology (QSP) modeling and simulation support for Phase 1 clinical trials.
Applied BioMath will:
- Work with the clinical and biomarker sub-teams at Jounce to support scientific aspects and implementation of the PKPD strategy in the Phase 1 trial
- Provide real time clinical pharmacology support including data analysis and visualization
- Author the PKPD analysis plan included in the final clinical study report
"Applied BioMath is an extension of our team. We work iteratively and closely with them and this results in a transparency and trust that is a win-win for both teams. We trust their results and have reaped great value from our interactions with Applied BioMath. For example – working with Applied BioMath on QSP approaches supporting the IND allowed us to justify a first in human dose to regulatory agencies which could help accelerate our clinical timelines."
Dr. Elizabeth Trehu, MD, Chief Medical Officer at Jounce Therapeutics